AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

AstraZeneca has reported a jump in quarterly sales thanks to record growth in its all-important US business, as the UK’s biggest drugmaker prepares to invest billions in the market ahead of potential ...

AstraZeneca has announced an ambitious $50 billion investment in the United States, aiming to significantly expand its ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

LONDON] British pharmaceutical giant AstraZeneca on Tuesday (Jul 29) said net profit rose 27 per cent in the second quarter, ...

CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...